Cancer Stemness Meets Immunity: From Mechanism To Therapy (Part 2)

Jun 09, 2022

Xav paub ntau ntxiv plz hu raudavid.wan@wecistanche.com

Hauv ntau hom mob qog noj ntshav, macrophage thiab microglia txoj hauv kev thiab / lossis cov khoom muaj feem cuam tshuampro- qogpolarization muaj xws li STAT3, nuclear factor (NF)-kB, thiab PI3Ky txoj kev (Kaneda li al., 2016; Qian thiab Pollard, 2010). Ntawm cov no, STAT3 transcription factor plays lub luag haujlwm tseem ceeb. Macrophage STAT3 yog qhib los ntawm CSC-derived IL-6, L-10, thiab/los yog exosome cargo, uas ua rau muaj kev tswj ntawm cov noob.txhawb - qogprogramming thiab inhibition ntawm cov noob encoding los tiv thaiv qog cytokines (Malyshev thiab Malyshev, 2015). Ntxiv mus, STAT3 inhibition abolishes CSC-induced pro-mob macrophage polarization hauv GBM (Gabru-siewicz li al., 2018; Wu et al., 2010; Yao et al, 2016), mob qog noj ntshav (Kobatake li al, 2020), thiab mob cancer mis (Weng et al., 2019). Txoj kev NF-kB yog qhov tseem ceeb rau CSC-induced pro-tumor macrophage polarization nyob rau hauv zes qe menyuam cancer (Deng li al.2015). Hauv cov ntsiab lus, txoj kev tshawb fawb ntawm CSC-induced macrophage polarization tau txheeb xyuas qhov tseem ceeb thiab kho tau txoj hauv kev macrophage hauv cov qog nqaij hlav tshwj xeeb (Table 1).

1654743153355

Nyem qhov no kom paub ntau ntxiv txog Cistanche

TAMs Txhawb Kev Mob Cancer Stemness thiab CSC Niche Mirroring CSC kev ua, TAMs tuaj yeem txhawb nqa CSC stemness thiab CSC niche (Daim duab 3). Lub niche yog qhov tseem ceeb tshwj xeeb hauv kev saib xyuas ntawm CSC tus kheej rov ua dua tshiab, muaj peev xwm rov ua dua tshiab, thiab pib qog hlav. Qhov kev txhawb nqa microenvironment no yog tsim los ntawm cov qog nqaij hlav cancer, lub cev tiv thaiv kab mob, cov kab mob mesenchymal qia hlwb (MSCs), fibroblasts, endothelial cells, thiab extracellular matrix (ECM) Cheebtsam (Daim duab 3; Plaks li al, 2015). Paracrine yam muab tau los ntawm ntau hom stromal cell no ua lub luag haujlwm tseem ceeb hauv kev txhawb nqa CSC stemness hauv niche. Tshwj xeeb, hauv cov qog nqaij hlav hauv lub mis thiab txoj hnyuv, MSCs pab txhawb rau CSC niche tsim los ntawm kev zais cov prostaglandin E2(PGE2), IL-6, IL-8, thiab CXCL1(Liet al.2012). Fibroblasts tuaj yeem ntxias cov kab mob metastatic rau mob qog noj ntshav CSCs los ntawm kev tso tawm ntawm POSTN (Malanchi li al, 2011). TAMs tsim cov yam ntxwv los ua kom muaj cov kabmob kheesxaws sib txawv kom tau txais CSC-zoo li cov yam ntxwv thiab ua kom muaj CSC stemness hauv qog noj ntshav mis (Lu li al, 2014),qhov ncauj squamous cell carcinoma(Li et al.,2019), lub raum cell carcinoma (Yang et al.,2016), hepatocellular carcinoma (HCC)(Wang et al.,2016), and pancreatic cancer (Mitchem et al,2013). Raws li txoj cai, depletion ntawm TAMs los ntawm inhibition ntawm colony-stimulating factor 1 receptor (CSF1R) thiab CC motif chemokine receptor 2 (CCR2) diminishes cov qog-initiating zog ntawm CSCs hauv cov qauv nas (Mitchem li al, 2013).In GBM, TAM kev txhawb nqa. ntawm CSC niche nyob ntawm nws cov pro-mob phenotype, thiab reprogramming mus rau ib qho kev tiv thaiv qog phenotype (siv amphotericin Bor vitamin B3) attenuates mob qog noj ntshav stemness thiab tumorigenicity nyob rau hauv vitro thiab vivo thiab sensitizes cov qog no mus rau chemotherapy (Sarkar 2. , 2020). Cov kev tshawb pom no qhia txog qhov kev kho mob muaj peev xwm cuam tshuam rau CSC niche ntawm reprogramming TAMs mus rau kev tiv thaiv qog phenotype.

1654743214514

Qhov tseem ceeb ntawm TAMs hauv CSC biology yog txhawb nqa los ntawm cov npe loj hlob ntawm TAM-los ntawm yam cuam tshuam rau kev saib xyuas ntawm CSC stemness. Table 2 piav qhia txog cov xwm txheej zoo li no thiab lawv cov txheej txheem ua haujlwm hauv cov qauv mob qog noj ntshav sib txawv. EMT yog cov txheej txheem tseem ceeb uas ua rau cov qog nqaij hlav qog noj ntshav kom tau CSC-zoo li cov yam ntxwv thiab tuav CSC stemness (Biddle and Mackenzie, 2012). Hauv cov qog nqaij hlav cancer mis, EMT cuam tshuam nrog kev tswj hwm ntawm CD90 thiab EphA4, uas kho lub cev sib cuam tshuam ntawm CSCs thiab TAMs (Lu et al, 2014). Raws li qhov tshwm sim, TAMs tuaj yeem ua kom mob qog noj ntshav ntawm lub mis EMT ntxiv, yog li ua rau muaj kev tawm tswv yim zoo los txhawb CSC stemness los ntawm kev zais ib lub vaj huam sib luag ntawm CSC-txhawb cytokines, xws li IL-6, IL-8, thiab IL-1 (Guo et al.,2019a; Let al.,2014; Valeta-Magara li al,2019). Ib yam li ntawd, cov ntaub ntawv pov thawj qhia tau tias TAMs hauv GBM (Hide li al, 2018), HCC (Fan et al, 2014; Wan et al, 2014), pancreatic cancer (Nomura et al, 2018; Saint al., 2015; Zhang et al. .,2019a), thiab qog noj ntshav zes qe menyuam (Raghavan li al.,2019) tuaj yeem txhawb nqa qog nqaij hlav cancer EMT thiab/lossis zais ntau yam CSC-txhawb cytokines (xws li IL-1 , IL-6, thiab TGF -), yog li txhawb CSC stemness, qog kev loj hlob, thiab kev kho mob. Ntxiv rau cytokines, TAMs tuaj yeem tsim cov yam ntxwv tshwj xeeb los txhawb CSC stemness. Piv txwv li, CCL5, pleiotrophin (PTN), globule-epidermal growth factor-Val (MFG-E8), thiab CCL8 yog qhov nyiam tshaj tawm thiab zais cia los ntawm TAMs hauv prostate cancer (Huang et al, 2020), lymphoma (Wei et al, 2019b ), kab mob qog noj ntshav (CRC) (Jinushi li al, 2011), thiab GBM (Zhang li al, 2020), raws li, qhov uas lawv txhawb CSC qia thiab qog hlav. Thaum kawg, ntxiv rau cov ntsiab lus soluble, TAMs tuaj yeem txhawb CSC stemness los ntawm kev sib cuam tshuam ncaj qha. Tshwj xeeb, hauv kev mob qog noj ntshav mis, daim siab, thiab cov qog nqaij hlav sinusoidal endothelial cell C-hom, lectin yog ib qho transmembrane protein uas tau nthuav tawm ntawm TAMs uas cuam tshuam nrog hydrophilic subfamily 3 tus tswvcuab A3 receptor ntawm cov qog nqaij hlav los txhim kho stemness (Liu li al., 2019) . TAM-derived yam thiab TAM-mob qog noj ntshav ntawm lub cev sib cuam tshuam ua kom muaj ntau txoj hauv kev hauv cov qog nqaij hlav cancer uas yog qhov tseem ceeb rau kev saib xyuas ntawm qia. Cov CSC txoj hauv kev tseem ceeb no suav nrog STAT3, SHH, thiab NOTCH (Han et al, 2015; Hirata li al., 2014; Zhang li al., 2019b), nrog rau PI3K / AKT, WNT / -catenin, thiab NANOG (Morgan thiab al, 2018; Wang et al, 2010b, 2019a; Wei et al, 2013; Zhang et al, 2019c). Cov ntaub ntawv pov thawj muaj txhawb qhov kev pom tias TAM-derived yam tseem ceeb ua rau txoj hauv kev no los txhim kho lossis tswj CSC qia (Table 2). Ntawm lawv, STAT3 zoo nkaus li tseem ceeb tshaj plaws los ntawm nws txoj kev tswj hwm lub zog ntawm cov noob caj noob ces thiab kev ua kom lub cev txhawb nqa txoj hauv kev, xws li NF-kB (Galoczova et al.2018). Raws li, STAT3/NF-kB inhibition abolishes TAM-promoted stemness nyob rau hauv lub mis mob cancer (Lu li al., 2014; Val-eta-Magara li al, 2019; Yang et al, 2013), HCC (Li et al, 2017; Wan thiab al, 2014), prostate cancer (Huang li al, 2020), pancreatic cancer (Mitchem li al, 2013; Nomura li al., 2018), thiab CRC (Jinushi li al, 2011). Txoj hauv kev WNT / -catenin thiab SHH tuaj yeem txhawb CSC stemness hauv qee qhov chaw. Aberrant activation ntawm WNT signaling, muaj nyob rau hauv ntau hom qog, feem ntau txhais CSC lub xeev thiab kev saib xyuas ntawm CSC biology (de Sousa E Melo thiab Vermeulen, 2016). Cov kab lis kev cai ntawm tes thiab nas cov qauv qhia tau hais tias TAMs qhib txoj hauv kev WNT / -catenin hauv CSCs thiab inhibition ntawm txoj kev no cuam tshuam TAM-induced upregulation ntawm CSC stemness hauv HCC (Chen li al., 2019b), prostate cancer (Huang li al., 2020), thiab lymphoma (Wei et al, 2019b). Ib yam li ntawd, SHH txoj hauv kev tau cuam tshuam rau kev tswj hwm CSC stemness ncaj qha lossis los ntawm kev cuam tshuam nrog lwm txoj hauv kev cuam tshuam, xws li TGF- (Takebe li al., 2015). Nrog rau TAM-txhawb CSC stemness, CRC cia siab rau SHH txoj kev (Jinushi li al,2011), mob qog noj ntshav ntawm TGF- 1/SMAD2/3/NANOG txoj kev (Zhang li al,2019a), HCC ntawm txoj kev NOTCH (Wang et al.2016), mob cancer mis ntawm v-src sarcoma (Schmidt-Ruppin A-2) kab mob oncogene homolog (avian) (SRC) pathway (Lu et al, 2014), thiab glioma ntawm txoj kev ntxiv-cellular tswj kinase 1/2 (ERK1/2) (Zhang li al.2020). Ua ke, cov kev tshawb pom no qhia txog STAT3 / NF-kB thiab WNT / -catenin raws li txoj hauv kev tseem ceeb rau TAM-induced CSC stemness. Txawm li cas los xij, kev sib txawv ntawm txoj hauv kev hla ntau cov qog nqaij hlav qhia txog qhov xav tau los tsim cov ntsiab lus tshwj xeeb rau lub hom phiaj rau lawv.

1654743258556

CSC-MDSC Crosstalk

Qhov cuam tshuam ntawm CSCs ntawm MDSC Biology

MDSCs yog cov neeg sib txawv ntawm cov hlwb myeloid uas suav nrog granulocytic lossis polymorphonuclear (PMN-MDSC) thiab monocytic (M-MDSC) pawg (Gabrilovich thiab Nagaraj 2009).PMN-MDSCs suav nrog ntau dua 80 feem pua ​​​​ntawm tag nrho MDSCs, thiab M-MDSCs. tuaj yeem sib txawv rau hauv TAMs (Gabrilovich, 2017; Kumar et al., 2016).MDSCs yog tsim nyob rau hauv cov pob txha pob txha thiab recruited rau hauv cov qog los ntawmqog-derived chemokines, xws li CCL2 thiab CCL5. Zoo ib yam li TAMs, MDSCs ua lub luag haujlwm tseem ceeb hauv kev tswj cov qog angiogenesis, kev loj hlob, metastasis, thiab kev tiv thaiv kab mob (Gabrilovich, 2017; Kumar et al 2016). Cov ntaub ntawv pov thawj ntxiv kuj tau qhia txog kev sib cuam tshuam ntawm CSCs thiab MDSCs hauv TME, qhov twg CSCs pab txhawb rau MDSC infiltration, nthuav dav, thiab ua kom muaj zog los ntawm kev tso tawm ntawm cov ntsiab lus soluble thiab exosomes hauv ntau hom mob qog noj ntshav (Daim duab 4; Table 3). Hauv SCCHN, piv nrog CD44cells, CD44 * CSCs secrete ntau dua ntawm IL-8, granulocyte-macrophage colony-stimulating factor (GM-CSF), thiab TGF- thiab ua rau cov neeg loj dua ntawm MDSCs thaum lawv koom nrog. peripheral ntshav mononuclear hlwb (PBMCs) (Chika-matsu li al., 2011).In GBM, GSCs tsis tsuas yog txhawb kev sib txawv ntawm PBMCs rau hauv M-MDSCs los ntawm kev tso tawm ntawm exosomes (Do-menis li al., 2017) tab sis kuj qhib MDSCs. txhawm rau tiv thaiv lub cev tiv thaiv kab mob los ntawm kev tso tawm ntawm macrophage migration inhibitory factor (MIF) (Otvos li al, 2016). Hauv melanoma, kev qhia ntawm miR-92 hauv CD133 ntxiv rau CSCs raug txo qis thaum piv rau CD133- hlwb, uas txhawb nqa kev qhia ntawm TGF- ntawm txoj kev x5 integrin/SMAD2, ua rau ntau PMN-MDSCs. hauv TME (Shidal et al, 2019). MDSCs Txhawb CSC Stemness

1654743302476

Thaum MDSCs nkag mus rau hauv TME, lawv tuaj yeem sib txuas lus txhawb nqa CSC stemness ntawm cov txheej txheem sib txawv hauv ntau hom mob qog noj ntshav (Daim duab 4; Table 3). Hauv kev mob qog noj ntshav ntawm zes qe menyuam, MDSCs induce miR-101 thiab GM-CSF qhia nyob rau hauv cov qog nqaij hlav cancer, uas nce stemness ntawm upregulation ntawm corepressor noob C-terminal binding protein-2 (CtBP2)(Quiet al,2013) thiab ua kom txoj hauv kev STAT3 (Li et al., 2020), feem. Hauv ntau yam myeloma, PMN-MDSCs ua rau kev qhia ntawm piwi-inter-acting RNA piRNA-823 hauv cov qog nqaij hlav cancer, uas txhawb nqa stemness los ntawm kev ua kom DNA methyltransferase 3B (DNMT3B) los pab txhawb DNA methylation(Ai li al.,2019 ). Txawm hais tias cov ntaub ntawv no qhia txog lub luag haujlwm tseem ceeb ntawm MDSCs hauv kev txhawb nqa qog nqaij hlav qog noj ntshav, cov cim ntawm MDSC-los ntawm cov xwm txheej hauv cov mob qog noj ntshav no tseem tshwm sim. Ntawm qhov kev ceeb toom, STAT3 dua zoo li yog ib txoj hauv kev tseem ceeb rau lub stemness. Hauv cov qog nqaij hlav hauv lub mis thiab pancreatic, MDSCs zais IL-6(hauv ob hom mob qog noj ntshav) thiab nitric oxide (hauv kev mob qog noj ntshav mis) txhawm rau qhib STAT3 thiab NOTCH txoj hauv kev los txhawb stemness (Panini li al,2014; Peng li al,2016) . Hauv kev mob qog noj ntshav mis, qhib STAT3 txhawb nqa kev ua haujlwm ntawm NOTCH, uas ua kom yooj yim rau kev ua kom STAT3 tsis tu ncua, yog li tsim cov lus tawm tswv yim los txhawb nqa lub cev (Peng li al., 2016). Ntxiv rau qhov stemness, M-MDSC-derived NOS2 kuj tseem tuaj yeem txhawb EMT los ntawm kev ua haujlwm ntawm STAT3 txoj hauv kev, uas ua rau cov qog nqaij hlav qog noj ntshav thiab metastasis (Ouzounova li al, 2017).In CRC, PMN-MDSCs tuaj yeem zais exosomal S100A9 los txhawb kev mob qog noj ntshav. cell stemness los ntawm kev ua kom lub STAT3 thiab NF-kB txoj kev, uas yog ntxiv amplified nyob rau hauv hypoxic mob (Wang li al.,2019b),

tsim NF-kB hauv MDSC-induced stemness. Tseeb tiag, MDSCs yog qhov tseem ceeb ntawm PGE, hauv ntau hom mob qog noj ntshav (xws li, zes qe menyuam, qog noj ntshav, thiab endometrial cancers; Komura li al, 2020; Kuroda li al., 2018; Yokoi li al., 2019), uas tuaj yeem txhawb nqa. mob qog noj ntshav stemness los ntawm activating NF-B ntawm E-type prostanoid receptor 4 (EP4)-Pl3K thiab EP4-mitogen-activated protein kinase (MAPK) txoj kev (Wang li al, 2015). Yog li, ntau yam thiab txoj hauv kev hauv qab MDSC-CSC kev sib cuam tshuam, thiab STAT3 thiab NF-kB yog qhov tseem ceeb dua.

1654743367081

CSC-T Cell Crosstalk

Kev cuam tshuam ntawm CSCs ntawm T Cell Biology

Kev txheeb xyuas suav tau kuj tau qhia txog kev sib raug zoo ntawm cov qog nqaij hlav qog noj ntshav thiabCD8t T cellHauv ntau hom mob qog noj ntshav (Miranda li al., 2019).Hauv SCCHN, GBM, thiab melanoma, siab stemness cuam tshuam nrog kev qhia qis ntawm cov qog nqaij hlav qog nqaij hlav thiab lub cev tiv thaiv kab mob (xws li CD86, CD40, loj histocompatibility complex [MHC] Il, transporter txuam nrog antigen ua, histocompatibility leukocyte antigen [HLA]-A2, melanoma antigen lees paub los ntawm T-cells 1, melanoma inhibitor ntawm apoptosis, New York esophageal squamous cell carcinoma 1, thiab melanoma- txuam nrog antigen-A) thiab kev qhia siab ntawm kev tiv thaiv kab mob tiv thaiv kab mob (xws li PD-L1; Chikamatsu li al., 2011; Schatton li al., 2010; Wei et al., 2010). Raws li cov kev sib raug zoo no, CSCs tswj qhov muaj pes tsawg leeg thiab kev ua haujlwm ntawm T hlwb los ntawm ntau qhov kev sim ua haujlwm tau zoo (Daim duab 4; Table 4). Ua ntej, hauv GBM, GSCs tsim TGF- , CCL2, thiab galectin -3, uas txwv tsis pub CD8 ntxiv thiab CD4 ntxiv rau T cell activation thiab proliferation (Wei li al, 2010). Thib ob, GSC exosome tenascin-C (TNC) koom nrog x5 1 thiab ib 5 6 integrins ntawm T hlwb kom txo qis AKT / mTOR signaling thiab inhibit T cell activation thiab proliferation (Domenis li al, 2017; Mizaei et ib., 2018). Thaum kawg, hauv prostate cancer, CSCs secrete TNC los inhibit qhov ua kom thiab loj hlob ntawm CD8 ntxiv thiab CD4 ntxiv rau Tcells ntawm kev sib cuam tshuam nrog x5 1 integrin ntawm T hlwb (Ja-chetti li al.,2015).

1654743435751

T-reg cells yog cov kab mob tiv thaiv kab mobCD4 plus T cellsCSCs nyiam thiab qhib T-reg hlwb ntawm ntau yam soluble (Daim duab 4; Table 4), suav nrog, Tshwj xeeb tshaj yog, TGF-, uas tswj T-reg cell recruitment thiab expansion. Piv txwv li, CSCs tuaj yeem tsim cov qib siab ntawm TGF- hauv SCCHN (Chikamatsu li al., 2011), GBM (Wei et al., 2010), thiab melanoma (Shidal li al, 2019), uas nyob rau hauv lem txhawb T-reg cell. Kev nrhiav neeg ua haujlwm thiab nthuav dav los ntawm kev ua kom lub a5 integrin / niam tawm tsam decapentaplegic homolog 2 (SMAD2) txoj hauv kev, yog li inducing T cell apoptosis thiab inhibiting T cell proliferation thiab ua kom. Tsis tas li ntawd, ob peb CC chemokine cov neeg hauv tsev neeg, xws li CCL1 (Xu et al, 2017a), CCL2 (Wei et al, 2010), thiab CCL5 (You et al., 2018), tau pom tias muaj ntau yam tsim los ntawm CSCs hauv Hom mob qog noj ntshav, qhov twg lawv tuaj yeem txhawb kev nkag mus ntawm T-reg hlwb rau hauv TME. Ua ke, CSC-secreted TGF- thiab cov chemokines tshwj xeeb ua lub luag haujlwm tseem ceeb hauv T-reg cell recruitment thiab nthuav dav hauv TME. T Cells tswj CSC Stemness

cistanche bodybuilding

Cov ntaub ntawv pov thawj tshwm sim qhia tau hais tias cov khoom sib txawv ntawm T hlwb tuaj yeem tswj CSC stemness (Daim duab 4; Table 4). Hauv GBM, T-cell-conditioned nruab nrab inhibits GSC tus kheej-renewal ntawm secretion ntawm TNF- thiab interferon (IFN)-r (Mirzaeiet al, 2018).InNSCLC, CD8 ntxiv rau Tcells yog lub ntsiab qhov chaw ntawm IFN-Y, qhov twg tsawg. theem ntawm IFN- txhawb CSC stemness los ntawm kev ua kom PI3K / AKT / NOTCH1 txoj hauv kev thiab qib siab ntawm IFN-y induce cancer cell apoptosis los ntawm kev ua kom lub Janus kinase 1 (JAK1) / STAT1 / caspase txoj kev (Song et al., 2019 ) Hauv kev mob qog noj ntshav pancreatic, infiltrating Th2 hlwb tsim cytokines{19}} thiab IL-13 los qhib txoj hauv kev JAK1/STAT6 hauv cov qog nqaij hlav, uas ua rau MYC-tsav glycolysis (Dey li al, 2020), cov txheej txheem anabolic uas txhawb nqa CSC stemness (Chen et al, 2020b; Sancho et al., 2015). Ntxiv nrog rau qhov tso tawm ntawm cov kua dej tsis zoo, T hlwb tuaj yeem tswj CSC stemness los ntawm kev sib txuas ncaj qha ntawm tes-rau-cell mechanism nyob rau hauv mob qog noj ntshav uas cognate non-lytic kev sib cuam tshuam ntawm CD8 ntxiv rau T hlwb thiab qog nqaij hlav cancer tuaj yeem txhawb kev mob qog noj ntshav (Stein et ib., 2019).

Ntxiv nrog rau cov nyhuv T-cell, T-reg cells thiab Th17 hlwb kuj tuaj yeem tswj cov qia. Piv txwv li, hauv AML, T-reg hlwb secrete IL-10 los txhawb lub stemness ntawm leukemic qia hlwb los ntawm kev ua kom PI3K/AKT/OCT4/NANOG txoj kev (Xu li al.,2017b). Lub stemness-txhawb cov nyhuv ntawm T-reg hlwb kuj pom nyob rau hauv mob cancer ntawm lub mis, qhov uas tsis paub-reg cell soluble yam upregulate stemness-txog txoj kev: SOX2; NAOG; thiab OCT4 (Xu et al, 2017a).In HCC, T-reg cells secrete TGF- los txhawb CSC stemness los ntawm kev txhawb nqa EMT(Shi et al, 2018a; Xu et al, 2009), whereas, hauv CRC, T-reg- cell-derived TGF- drives cancer cell dedifferentiation (Nakano li al, 2019), qhia txog cov ntsiab lus tshwj xeeb ntawm TGF- hauv CSCs. Cov kev soj ntsuam no tau ua raws li cov kev paub zoo ntawm TGF- hauv kev mob qog noj ntshav (Massagué, 2008). Txawm hais tias Th17 yog ib feem ntawm T pab-er hlwb uas kho cov kab mob qog nqaij hlav tiv thaiv kab mob (Guery thiab Hugues, 2015), IL-17 los ntawm Th17 hlwb lossis CD4 ntxiv rau Tcells kuj txhawb nqa CSC stemness los ntawm kev ua kom NF-kB thiab p38 MAPK txoj hauv kev hauv cov qog nqaij hlav zes qe menyuam thiab pancreatic (Kiang li al., 2015; Zhang et al, 2018) thiab STAT3 txoj hauv kev hauv plab hnyuv (Jiang et al., 2017). Tsis tas li ntawd, IL-17 tuaj yeem hloov kho hauv T-reg hlwb nyob rau hauv cov mob hypoxic, uas ua rau txhawb nqa CSC stemness hauv CRC (Yang li al., 2011). Yog li, sib txawv T cell subsets pab txhawb rau kev saib xyuas ntawm CSCs ntawm ntau yam mechanisms uas muaj cov yam ntxwv soluble thiab kev sib cuag ntawm tes.

Therapeutic Potential ntawm InterceptingCSC-ImmuneCell Crosstalk

Targeting CSC-TAM Crosstalk

Cov kws kho mob tseem ceeb thiab kev kho mob tseem ceeb tau nrhiav kev tsom mus rau cov yam ntxwv sib txawv ntawm cov kab mob biologic thiab cov kev taw qhia tseem ceeb ntawm CSCs thiab TAMs, raws li tau tshuaj xyuas yav dhau los (Agliano li al., 2017; Pathria et al., 2019; Zhao et al., 2018). Raws li tau sau tseg hauv daim duab 5, kev sim tshuaj uas tuaj yeem tsom CSC biology suav nrog inhibitors ntawm SHH, NOTCH, WNT / -catenin, STAT3, thiab NANOG txoj hauv kev (Agliano li al., 2017; Zhao et al., 2018) thiab anti-CD44 tshuaj tiv thaiv (Menke-van der Houven van Oordt li al., 2016). Txog niaj hnub no, SHH inhibitor, vismodegib, tau raug pom zoo rau cov kab mob metastatic lossis hauv zos basal cell carcinoma (Sekulic li al., 2012), thiab kev sim tshuaj tseem tab tom ua rau cov neeg ua haujlwm tsom rau kev nrhiav neeg ua haujlwm macrophage (CR2, CXCR4, integrin subunit alpha 4 [ITGA4). ] thiab ITGA5 inhibitors), polarization (xws li receptor 4 [TLR4], TLR7, TLR9, thiab CD40 activators thiab PI3Ky inhibitor), thiab ciaj sia taus (CSF1R inhibitors; Gregoire li al., 2020; Pathria li al., 2019). Txawm li cas los xij, txawm hais tias qhov kev thov rov hais dua ntawm CSC-tus neeg saib xyuas, cov lus teb zoo heev tsis tau pom, tej zaum vim tsis muaj qhov tshwj xeeb CSC lub hom phiaj (Agliano li al.,2017; Turdo li al.,2019) nrog rau cov yas siab ntawm CSC, uas ua rau kev poob thiab rov ua kom muaj zog

Raws li kev sib txawv ntawm TME (Agliano li al., 2017; Müller li al., 2020; Plakset al., 2015). Ib yam li ntawd, TAM-targeted therapies, xws li CSF1R inhibition, tau qhia meager anti-tumor teb hauv GBM vim yog ib feem ntawm tsis kam lees los ntawm kev qhib Pl3K teeb liab hauv glioma hlwb (Quail li al, 2016).

Nws yog kev ntxias kom xav tias kev tsom mus rau kev txhob txwm tshaj tawm kev sib koom ua ke ntawm CSCs thiab TAMs thiab lawv cov plasticity hauv cov ntsiab lus tshwj xeeb tuaj yeem ua rau cov lus teb muaj zog dua. Piv txwv li, IL-6/STAT3 thiab Pl3K yog qhov tseem ceeb rau kev tswj hwm ntawm CSCstemness thiab macrophage pro-tumor polarization hauv ntau hom qog; inhibition ntawm txoj hauv kev no tau qhia txog kev tiv thaiv qog nqaij hlav (Agliano li al., 2017; Kobatake li al., 2020; Pathria li al, 2019; Weng et al, 2019). Tsis tas li ntawd, xaiv cov neeg mob siab CSC thiab TAM kos npe tuaj yeem txhim kho cov lus teb rau cov neeg sawv cev rau txoj hauv kev no (Agliano li al, 2017; Pathria et al, 2019). Cov kev sim no tuaj yeem tau txais txiaj ntsig ntxiv los ntawm kev soj ntsuam pharmacodynamic ntawm seb cov neeg ua haujlwm no puas tuaj yeem hloov kho txoj hauv kev no thiab lawv cov qog nqaij hlav biology (Daim duab 5). Thaum kawg, muab lub plasticity ntawm cov txheej txheem no, cov kev tshawb fawb pharmacodynamic yuav tsum tau ua kom tiav los ntawm kev sib koom ua ke omic tsom xam ntawm kev hloov kho cov lus teb rau cov kev kho mob, uas tuaj yeem qhia ntxiv txog kev sim ua ke ntawm cov neeg ua haujlwm sib koom ua ke.

Ib lub tswv yim txaus siab los cuam tshuam CSC-TAM crosstalk tuaj yeem suav nrog kev thaiv ntawm CD47-cov cim qhia kev tswj hwm protein alpha (SIRPa) txoj hauv kev. CD47 yog transmembrane protein uas qhia txog CSCs thiab qog nqaij hlav cancer uas ua haujlwm raws li "tsis txhob noj kuv" teeb liab (Cioffi li al.2015); Kev sib cuam tshuam ntawm CD47 nrog SIRPa ntawm macrophages ua rau inhibition ntawm phagocytosis los ntawm TAMs (Matozaki li al, 2009). Anti-CD47 therapy tsub kom CSC phagocytosis hauv vitro thiab txo cov qog nqaij hlav hauv vivo (Chan et al, 2009; Coffi et al., 2015; Majeti li al., 2009), uas yog ntxiv augmented thaum qhov kev kho no ua ke nrog tshuaj kho mob (Cioffi et al, 2015). Ntau qhov kev sim tshuaj ntsuam xyuas monoclonal anti-CD47 cov tshuaj tiv thaiv kab mob (Hu5F9-G4, SFR231, CC-90002, thiab IBlI188) thiab cov tshuaj tiv thaiv me me (TTI-621 thiab ALX148) tab tom ua (Daim duab 5 ; Gregoire et al., 2020; Pathria et al, 2019). Lwm lub sijhawm los cuam tshuam CSC-TAM crosstalk chaw zov me nyuam ntawm lub hom phiaj soluble yam uas reciprocally txhawb txhua hom cell. Piv txwv li, inhibition ntawm CSC-specific POSTN thiab nws txoj kev cuam tshuam (Zhou et al, 2015) lossis TAM-derived CCL5 (Huang et al, 2020) tau pom tias cuam tshuam CSC-TAM crosstalk, suppress qog loj hlob, thiab txuas ntxiv kev ciaj sia. nyob rau hauv nas qauv ntawm GBM thiab prostate cancer.

cistanche deserticola bodybuilding

Ntawm cov lus pom zoo dua, tus qauv ntawm kev saib xyuas cov kws khomob tau pom cov lus cog tseg rau cov kab mob metastatic siab heev vim muaj tshuaj lom thiab kev loj hlob sai ntawm kev tiv thaiv. Raws li CSCs thiab TAMs ua lub luag haujlwm tseem ceeb hauv kev txhim kho cov tshuaj tiv thaiv (Agliano li al., 2017; De Palma thiab Lewis, 2013), kev cuam tshuam ntawm CSC-TAM crosstalk tuaj yeem txhim kho nws cov lus teb rau kev siv tshuaj khomob. Raws li cov kab no, CSCs nyob rau hauv chemo-resistant qog secrete cytokines los tsim ib tug pro-tumorigenic microenvironment los ntawm skewing macrophages mus rau ib tug apron-mob phenotype (Yama-shiniest al., 2014). Tseeb, depletion ntawm TAMsreduces CSCstem-ness inhibits metastasis thiab txhim kho chemotherapeutic teb nyob rau hauv pancreatic cancer (Mitchem li al, 2013). Mechanistically, TAMs txhawb CSC stemness thiab chemoresistance los ntawm kev tso tawm ntawm MFG-E8, uas tuaj yeem ua rau kev ua haujlwm ntawm STAT3 thiab SHH txoj hauv kev hauv CSCs ntawm CRC (Jinushi li al, 2011). Yog li, txuas cov pov thawj taw qhia rau lub peev xwm ntawm kev tsom mus rau CSC-TAM circuits rau kev kho mob qog noj ntshav tshiab nrog rau kev txhim kho kev siv tshuaj khomob zoo.

Hom phiajCSC-MDSCCrosstalk

Qhov tseem ceeb ntawm MDSCs hauv kev txhawb nqa qog loj hlob, metastasis, angiogenesis, CSC stemness, thiab kev tiv thaiv kev tiv thaiv kab mob tau txhawb nqa cov neeg ua haujlwm kuaj mob uas inhibit MDSCs (Fleming li al, 2018). MDSC inhibition cov tswv yim tsom rau kev nrhiav neeg ua haujlwm (xws li inhibition ntawm CCR5 thiab CXCR2), txhawb kev depletion (xws li, tyrosine-kinase inhibitors thiab chemotherapeutic agents), thiab thaiv kev tiv thaiv kab mob (xws li, inhibition ntawm STAT3, phosphodiesterase-5, thiab chav kawm I histone deacetylases; Fleming li al., 2018). Txawm li cas los xij, txoj kev loj hlob ntawm MDSC-kev kho mob yog cuam tshuam los ntawm heterogeneity ntawm MDSCs thiab tsis muaj cov cim cellular (Lu li al., 2019). Ntawd yog, MDSCs yog heterogeneous tsis paub tab myeloid hlwb tsim los ntawm PMN-MDSCs thiab M-MDSCs, uas muaj cov haujlwm lom neeg sib txawv. Tam sim no MDSC-cov neeg ua haujlwm tsom mus rau lub hom phiaj ob pawg MDSC thiab lwm hom xovtooj ntawm tes hauv TME. Tsis tas li ntawd, qhov tsis muaj cov cim tshwj xeeb rau tib neeg MDSCs thiab kev txheeb xyuas qhov sib npaug ntawm murine MDSCs tau cuam tshuam kev tshawb fawb kev txhais lus. Thaum kawg, MDSC qhov ceev thiab ua kom lub xeev tuaj yeem hloov pauv hloov pauv hauv TME.

Txawm hais tias cov kev cov nyom no, ntau lub tswv yim tsom rau CSC-MDSC crosstalk yog tsim nyog xav txog. Ib lub tswv yim yuav yog lub hom phiaj STAT3, uas yog ob qho tseem ceeb rau CSC kev saib xyuas thiab MDSC infiltration / activation, thiab inhibition ntawm STAT3 tau pom muaj zog tiv thaiv qog ua haujlwm cuam tshuam nrog kev cuam tshuam CSC stemness thiab MDSC infiltration / ua kom mob qog noj ntshav (Fleming li al. , 2018; Peng et al, 2016). Ib lub tswv yim thib ob yuav yog lub hom phiaj soluble uas txhawb nqa CSC-MDSC crosstalk. Piv txwv li, inhibition ntawm CSC-derived MIF los yog MDSC-derived IL-6 txuas ntxiv txoj sia nyob hauv nas qauv ntawm GBM (Otvos li al,2016) thiab mob qog noj ntshav mis (Peng li al.,2016). Ib lub tswv yim thib peb yuav koom nrog qhov kev tsis sib haum xeeb ntawm exosome-stimulated CSC-MDSC symbiosis. Tshwj xeeb, knockdown ntawm S100A9 hauv MDSC exosomes impairs STAT3 ua kom thiab inhibits qog loj hlob hauv nas qauv ntawm CRC (Wang li al, 2019b). Ua ke, ntau yam kev nkag siab ntawm cov tshuab no taw qhia txog kev cuam tshuam ntawm IL{18}}/STAT3 txoj hauv kev uas yog lub tswv yim los cuam tshuam nrog CSC-MDSC crosstalk thiab inhibit qog loj hlob. Hom phiajCSC-T CellCrosstalk

Kev sib cuam tshuam ntawm symbiotic ntawm CSCs thiab T hlwb kuj tseem tuaj yeem muab ntau cov tswv yim kho mob. Ua ntej, nyob rau hauv mob cancer ntawm lub mis, blockade ntawm CSC-derived T-reg cell txhawb nqa yam tseem ceeb, xws li CCL1, tau pom tias yuav inhibit qog loj hlob thiab T-reg cell infiltration (Xu li al, 2017a). Ib qho kev tiv thaiv qog nqaij hlav zoo sib xws tau pom nyob rau hauv tus qauv nas ntawm tus kab mob qog noj ntshav los ntawm inhibition ntawm T-cell-derived stemness sup-porting yam, xws li Th17 cell-derived IL-17, uas cuam tshuam loj heev qog loj hlob thiab CSC. stemness (Xiang et al, 2015). Qhov thib ob txoj hauv kev yog siv lub peev xwm ntawm T-cell-based immunotherapies, tshwj xeeb tshaj yog kev tiv thaiv kab mob tiv thaiv kab mob (ICI). Kev tiv thaiv qog noj ntshav ntawm ICls cuam tshuam nrog kev qhia ntawm lub cev tiv thaiv kab mob, xws li PD-L1, hauv TME (Ravidran li al., 2019). Tom qab ua kom cov STAT3 thiab NOTCH3/mTOR txoj hauv kev (Lee li al, 2016; Mansour li al., 2020), CSCs qhia ntau dua PD-L1 qib piv rau cov tsis-CSCs hauv ntau hom mob qog noj ntshav, suav nrog GBM, melanoma, SCCHN, CRC , mob qog noj ntshav, mob plab, thiab mob qog noj ntshav ntawm zes qe menyuam, uas PD-L1 tuaj yeem txhawb nqa CSC stemness, yog li ua rau muaj kev tawm tswv yim zoo (Gao li al,2019; Gupta li al.,2016; Ravindran li al.,2019; Wei thiab al.,2019a). Tsis tas li ntawd, qib PD-L1 tuaj yeem ua kom nthuav dav tom qab symbiotic CSC-immune cell sib cuam tshuam. Piv txwv li, MDSCs tuaj yeem txhawb nqa stemness thiab upregulate PD-L1 hauv CSCs los ntawm kev ua kom PI3K/AKT/mTOR txoj kev (Komura li al,2020). Yog li ntawd, CSCs secrete exosomes los tswj PD-L1 hauv macrophages los ntawm kev ua kom txoj hauv kev STAT3 (Gabrusie-wicket al, 2018). Ua ke, cov kev tshawb pom no taw qhia txog qhov muaj peev xwm siv tau ntawm IClagents, lub tswv yim txhawb nqa los ntawm kev kho cov tshuaj tiv thaiv PD1 txhim kho kev tiv thaiv qog nqaij hlav ntawm CSC cov tshuaj tiv thaiv hauv tus nas qauv ntawm lub zais zis (Shi li al.,2018b). Qhov thib peb txoj hauv kev yuav yog kev txhim kho cov kev kho mob sib xyaw ua ke tsom rau CSC-immune cell crosstalk thiab kev tiv thaiv kab mob. ICUs tsim cov lus teb zoo kawg nkaus hauv qee cov neeg mob qog noj ntshav; Txawm li cas los xij, feem ntau ntawm cov neeg mob tsis muaj lus teb. Kev tshawb fawb Mechanistic tau pom tias qhov ua tau zoo ntawm ICUs yog nyob ntawm TME (Murciano-Goroff li al., 2020). TAMs, MDSCs, thiab T-reg hlwb yog cov kab mob tiv thaiv kab mob tseem ceeb tshaj plaws hauv TME, uas lawv tsim kev sib cuam tshuam nrog CSCs, cuam tshuam nrog ib leeg, thiab txo qis T cell ua haujlwm (Daim duab 4). Mechanistically, TAMs thiab MDSCs tuaj yeem cuam tshuam T-cell-mediated los tiv thaiv qog cov lus teb los ntawm kev qhia siab ntawm lub cev tiv thaiv kab mob (xws li PD-L1, PD-L2, CD80, thiab CD86), tsim cov cytokines immunosuppressive (piv txwv li, IL-10 thiab TGF- ), thiab nrhiav neeg ua haujlwm ntawm cov tshuaj tiv thaiv kab mob T-reg rau hauv TME (Engblom li al.,2016; Kumar et al.,2016; Manto-vani et al, 2017). Cov kev tshawb fawb no qhia txog cov lus cog tseg ntawm TAM-lossis MDSC-cov phiaj xwm kev kho mob rau kev txhim kho ICl. Tseeb, lub cev loj hlob ntawm cov pov thawj pom tau tias cov kev kho mob macro-phage-targeted, xws li ua kom cov macrophage phagocytosis (Lian li al.,2019; Liu li al., 2018) lossis reprogram-ming ntawm TAMs los ntawm kev tiv thaiv qog. phenotype (Baer et al, 2016; Guerriero li al, 2017; Kaneda et al., 2016; Zhu et al., 2014), sib koom ua ke nrog ICls hauv ntau hom kab mob qog noj ntshav. Ib yam li ntawd, MDSC-targeted kev kho mob, los ntawm inhibiting MDSC infiltration (Flores-Toro li al.,2020; Highfillet al.,2014; Liao li al.,2019; Zhao li al.,2020) lossis thaiv MDSC ua kom (Davis li al, 2017; Liu et al, 2020; Lu et al., 2017), qhia kev sib koom ua ke zoo nrog ICUs hauv cov qauv nas. Cov kev tshawb fawb preclinical no tau ua rau muaj kev sim ua ke rau ntau hom mob qog noj ntshav (Hou li al., 2020; Pathria li al., 2019).

cistanche deserticola vs tubulosa

Xaus cov lus thiab cov kev xav yav tom ntej

Cov txheej txheem caj ces tau tswj hwm peb txoj hauv kev rau kev kho mob qog noj ntshav, tsim ntau tus neeg ua haujlwm tsom rau cov neeg tsav tsheb oncogenic cov xwm txheej hauv cov qog nqaij hlav cancer. Nyob rau hauv xyoo tas los no, kev ua tiav ntawm lub hom phiaj tiv thaiv kab mob thiab angiogenesis tau ua rau muaj kev txaus siab rau cov hom phiaj ua haujlwm hauv TME ecosystem. Qhov kev tshuaj xyuas no tshwj xeeb tau teev cov kab hluav taws xob molecular hauv qab kev sib cuam tshuam ntawm CSCs thiab lub cev tiv thaiv kab mob, suav nrog TAMs, MDSCs, thiab T hlwb, hauv kev kho mob qog noj ntshav. Qhov kev sib txuas lus sib txuas lus no tau tshwm sim nyob rau ntau theem, suav nrog CSC-qhib lub cev tiv thaiv kab mob kev ua haujlwm thiab kev ua haujlwm thiab lub luag haujlwm ntawm cov kab mob tiv thaiv kab mob no hauv kev txhawb nqa qog nqaij hlav qog noj ntshav thiab tsim kom muaj kev txhawb nqa CSC niche. Cov cwj pwm molecular ntawm CSC-immune cell symbiosis tau nthuav tawm cov tswv yim kho mob, suav nrog ob lub hom phiaj ntawm txoj hauv kev tseem ceeb tau qhib rau hauv CSCs thiab lub cev tiv thaiv kab mob (xws li, STAT3 thiab PI3K, cuam tshuam cov molecules lub luag haujlwm rau lub cev CSC-immune cell sib cuam tshuam (xws li CD. 47-SIRPa), thiab neutralizing soluble fac-tors uas reciprocally txhawb CSCs thiab lub cev tiv thaiv kab mob (xws li, IL-6).CSC- tiv thaiv kab mobKev sib cuam tshuam ntawm tes kuj tau qhia txog qhov tseem ceeb ntawm cov txheej txheem tshiab molecular no hauv kev tsav cov qog nqaij hlav, metastasis, thiab tshuaj tua kab mob. Yog li, lub hom phiaj ntawm lub voj voog molecular no muaj peev xwm cuam tshuam rau CSC-immune cell co-depend-denies thiab txhim khu kev ua tau zoo ntawm cov kev kho mob.

Txawm hais tias peb txoj kev paub txog CSC-kev tiv thaiv kab mob sib kis tau loj hlob zuj zus, ntau cov lus nug yuav tsum tau teb kom muaj txiaj ntsig zoo thiab ua kom lub cev hloov pauv kev nkag siab rau hauv cov kev kho tshiab. Ua ntej, ntau cov kev tshawb fawb soj ntsuam CSC-immune cell crosstalk tau tso siab rau cov qauv ntawm cov kab ke kev coj noj coj ua lossis cov hlwb cais tawm los ntawm cov qog nqaij hlav, uas qhia txog qhov xav tau rau kev tshawb fawb ntxiv uas siv hauv vivo qauv, kev txheeb xyuas caj ces, thiab kev soj ntsuam kev sib tw ntawm TME siv kab tracing. thiab nyob micro positron emission tomography (microPET) / xam tomography (CT) imaging technologies. Xws li cov qauv hauv vivo tuaj yeem ua tiav los ntawm cov kab lis kev cai organoid, uas zoo nkaus li muaj kev ncaj ncees rov hais dua cov yam ntxwv ntawm lawv cov ntaub so ntswg (Baker, 2018). Ntawd yog, cov kab mob qog noj ntshav thiab cov kab mob hauv lub cev tiv thaiv kab mob tuaj yeem ua haujlwm tau zoo dua thiab ntau dua cov qauv siv los kawm cov kev sib raug zoo thiab kev sib raug zoo ntawm CSCs thiab cov kab mob tiv thaiv kab mob thiab kuaj cov tshuaj tiv thaiv kab mob CSC-immune cell crosstalk. Qhov thib ob, qhov zoo tshaj plaws plasticity thiab heterogeneity ntawm ob qho tib si CSCs (hloov ntawm qia piv rau cov tsis-stem lub xeev) thiab lub cev tiv thaiv kab mob (xws li kev hloov pauv hauv thiab thoob plaws ntawm tes, xws li kev hloov pauv ntawm phenotypic spectrum hauv TAMs, kev sib txawv ntawm MDSC rau PMN- MDSC thiab M-MDSC pawg, thiab kev sib txawv ntawm M-MDSCs rau TAMs) qhia txog cov teeb meem hauv kev txheeb xyuas cov ntsiab lus tshwj xeeb ntawm CSC-immune cell circuits tseem ceeb ntawm cov qog nqaij hlav sib txawv thiab ntau hom mob qog noj ntshav, nrog rau kev hloov hauv CSC. -Immune cell sib cuam tshuam los ntawm kev kho mob. Yog li, kev siv lub peev xwm tag nrho ntawm kev tsom mus rau CSC-immune cell crosstalk yuav xav tau kev siv ntau ntawm siRNA-seq txhawm rau txheeb xyuas cov neeg tshiab thiab txheeb xyuas lub cev lub cev ntawm CSCs thiab lub cev tiv thaiv kab mob, nrog rau lawv cov lus sib tham hauv cov qog nqaij hlav tshwj xeeb thiab raug rau qee yam. kev kho mob. Xws li ib leeg-cell auditing yuav tsum tau ua kom tiav los ntawm kev ua haujlwm thiab kev tshuaj ntsuam genetic analyses siv nyob rau hauv vivo qauv systems los txheeb xyuas thiab validate lub hom phiaj thiab mechanisms tswj CSC-immune cell co-depend-tsis kam. Muab tus naj npawb ntawm cov xwm txheej cuam tshuam, bispecific anti-bodies dual lub hom phiaj tseem ceeb ua yeeb yam hauv kev hais kwv txhiaj hauvCSC-lub cev tiv thaiv kab mobCircuit Court yuav tsum tau xav txog. Thib peb, hla ntau hom qog nqaij hlav, IL-6/IL-6R/STAT3 txoj hauv kev zoo nkaus li yog qhov tseem ceeb tshaj plaws thiab tseem ceeb tsav tsheb ntawm CSC-immune cell cross-talk, raws li pov thawj los ntawm kev tshawb pom tias kws tshuaj inhibition ntawm IL-6R/STAT3 txoj hauv kev cuam tshuam cov qog nqaij hlav thiab rov ua rau CSC stemness, TAMs, thiab MDSCs hauv zais zis, mob cancer mis, thiab HCC nas qauv (Kobatake li al., 2020; Peng li al. , 2016; Wan et al., 2014). Txawm li cas los xij, kev tshawb xyuas ntxaws ntxiv ntawm kev ua ntawm cov tshuaj no yog xav tau, vim tias lawv tseem tsom mus rau lwm lub hlwb stromal hauv TME. Ntawd yog, cov kev ua los tiv thaiv qog yuav tsis cuam tshuam rau CSC-immune cell crosstalk thiab/lossis tej zaum yuav tsom mus rau stromal hlwb nrog kev tawm tsam rau CSCs, TAMs, thiab MDSCs. Hauv qhov no, cov qauv tsim los ntawm cov noob caj noob ces yuav muaj txiaj ntsig zoo los txiav tawm ntau lub luag haujlwm ntawm IL-6/L-6R/STAT3 txoj hauv kev tshwj xeeb hauv CSCs, TAMs, MDSCs, thiab/lossis T-cells piv rau Lwm cov hlwb hauv TME ecosystem. Thaum kawg, ntxiv rau TAMs, MDSCs, thiab T hlwb, kev tshuaj xyuas tsis ncaj ncees ntawm TGGA cov ntaub ntawv qhia tau hais tias kev mob qog noj ntshav siab siab cuam tshuam nrog txo qis NK hlwb (Miranda li al, 2019), qhia txog qhov muaj peev xwm CSC-NKcell crosstalk. CSCs feem ntau raug tua los ntawm activated NK hlwb; Txawm li cas los xij, lub cev loj hlob ntawm cov pov thawj qhia tau tias CSCs tuaj yeem tiv taus NK hlwb hauv qee hom mob qog noj ntshav, xws li GBM, AML, thiab mob qog noj ntshav mis (Sultan et al, 2017). Cov ntaub ntawv pov thawj tshwm sim qhia tau hais tias kev tiv thaiv CSC ntawm NK hlwb feem ntau nyob ntawm TME thiab tias NK cell activation tuaj yeem cuam tshuam los ntawm TAMs, MDSCs, thiab T-reg hlwb (Bruno li al, 2019; Ghiringhel li al, 2006; Kmeta et al, 2017). Ntxiv rau NK hlwb, cov pov thawj tsawg heev qhia tau hais tias mob qog noj ntshav ntawm tes muaj feem cuam tshuam nrog kev muaj cov hlwb dendritic (DCS), B-cells (Hsuet al., 2018; Miranda et al., 2019), thiab neutrophils (Hira li al. , 2015; Hwang et al., 2019). Txawm li cas los xij, qhov xwm txheej ntawm kev sib tham ntawm CSCs thiab plaub hom kab mob tiv thaiv kab mob no (NK hlwb, B hlwb, DCs, thiab neutrophils) tsis paub ntau. Yog li, kev tshawb fawb ntxiv uas qhia txog kev sib tham sib tham, nrog rau kev sib raug zoo ntawm plaub hom cell no nrog rau lwm lub cev tiv thaiv kab mob, suav nrog TAMs, MDSCs, thiab T hlwb, yuav ua rau txoj hauv kev rau kev tsim kho tshiab thiab zoo dua immunotherapies.

cistanche effects

Hauv cov ntsiab lus, peb tau nthuav tawm cov ntaub ntawv pov thawj uas cuam tshuam txog kev sib cuam tshuam ntawm CSC-kev tiv thaiv kab mob hauv lub cev raws li cov tsav tsheb ntawm kev loj hlob ntawm cov qog nqaij hlav uas muaj ntau yam kev mob qog noj ntshav thiab ua cov kev hloov pauv ntawm cov lus teb rau kev kho mob. Kev siv lub peev xwm kho mob ntawm cov kev sib cuam tshuam no yuav xav tau kev siv tau zoo ntawm lub hom phiaj thiab cov txheej txheem hauv qab no symbiotic kev sib raug zoo nrog rau kev nkag siab tob txog cov ntsiab lus lom neeg tshwj xeeb uas lawv ua si qhov tseem ceeb ntawm tus nqi txwv hauv kev tu qog. Kev ua tiav ntawm lub hom phiaj no yuav muaj txiaj ntsig zoo rau cov neeg mob qog noj ntshav.



Koj Tseem Yuav Zoo Li